Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > NanoLogix Applies for Provisional Patent Application For Innovative Treatment of Severe Sepsis

Abstract:
NanoLogix, Inc. (PINKSHEETS: NNLX) announced today that it has filed a provisional patent application with the U.S. Patent Office titled, "Antimicrobial Action of a Silver-Coated Nanotubular Dialysis Device."

NanoLogix Applies for Provisional Patent Application For Innovative Treatment of Severe Sepsis

SHARON, PA | Posted on February 20th, 2007

This provisional patent application is based around a new and unique methodology for treating severe sepsis and septic shock. The incidence of severe sepsis and septic shock is the major factor in over two hundred thousand deaths per year in the United States. During the past decades billions of dollars have been spent in developing treatment strategies for this major cause of morbidity and mortality. Almost all treatment strategies have been centered around the utilization of intravenous antibiotics. However, even today 20-35% of patients with severe sepsis and 40-60% of patients with septic shock die within thirty days, with further deaths occurring within the first six months of illness. Due to the fact that almost all of these patients must be treated in intensive care units, the cost of treating a single patient costs up to $10,000 per day, and the total cost to the American health care system is many billions of dollars per annum.

The NanoLogix invention treats bacteremia and septic shock by utilizing a silver nanoparticle-coated nanotubular dialysis unit for killing pathogenic micro-organisms present in a patient's blood stream. Prior to making this application NanoLogix scientists investigated this novel methodology against two bacterial strains (E.coli and Staphylococcus aureus) and one fungal strain (Candida albicans). In multiple experiments the pathogenic load of the micro-organisms went from colonies that were too numerous to count, down to zero or a very dramatically reduced number of colonies.

Mitchell S. Felder, M.D., the CEO and Chairman of the Board of NanoLogix, Inc. stated, "This is both a fascinating as well as truly innovative approach to conquering this major cause of hospital deaths worldwide. We hope to accelerate our investigation of this methodology, and are currently seeking to partner with a major university and/or health care organization. With further success and development, this technique could truly revolutionize the treatment of infectious diseases and save countless lives."

####

About NanoLogix
NanoLogix is an industry innovator in the research, development and commercialization of nano-biotechnologies, applications and processes. The Company owns or has the rights to 32 patented technologies. The Company is currently focused on the production of hydrogen from agricultural feedstock, industrial wastewater and municipal waste streams to create new sources of energy. NanoLogix is presently operating a hydrogen bioreactor at Welch's Food and has recently signed an agreement with the City of Erie Wastewater Treatment Plant for a prototype bioreactor installation. Additionally, NanoLogix develops and markets diagnostic test kits for use in early detection of infectious human diseases such as cancer, cystic fibrosis and AIDS, and owns a patent for the non-toxic induction of apoptosis ('cell suicide') for the treatment of cancer. For more information on the Company, visit http://www.nanologix.net.

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

For more information, please click here

Contacts:
Investor Relations.
Andrew Barwicki
516.662.9461

Copyright © Market Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Nano Ruffles in Brain Matter: Freiburg researchers decipher the role of nanostructures around brain cells in central nervous system function October 31st, 2014

Production of Biocompatible Polymers in Iran October 30th, 2014

Amorphous Coordination Polymer Particles as alternative to classical nanoplatforms for nanomedicine October 30th, 2014

'Electronic skin' could improve early breast cancer detection October 29th, 2014

Announcements

Nano Ruffles in Brain Matter: Freiburg researchers decipher the role of nanostructures around brain cells in central nervous system function October 31st, 2014

Gold nanoparticle chains confine light to the nanoscale October 31st, 2014

'Nanomotor lithography' answers call for affordable, simpler device manufacturing October 31st, 2014

Device invented at Johns Hopkins provides up-close look at cancer on the move: Microscopic view of metastasis could give insight about how to keep cancer in check October 31st, 2014

Patents/IP/Tech Transfer/Licensing

Device invented at Johns Hopkins provides up-close look at cancer on the move: Microscopic view of metastasis could give insight about how to keep cancer in check October 31st, 2014

Amorphous Coordination Polymer Particles as alternative to classical nanoplatforms for nanomedicine October 30th, 2014

Lomiko Signs Licensing Agreement to Produce and Supply Power Converter Systems to E-Commerce Customers October 29th, 2014

Researchers patent a nanofluid that improves heat conductivity October 22nd, 2014

Energy

Gold nanoparticle chains confine light to the nanoscale October 31st, 2014

Iranians Present Model to Predict Photocatalytic Process in Removal of Pollutants October 30th, 2014

New solar power material converts 90 percent of captured light into heat: SunShot Project aims to make solar cost competitive October 29th, 2014

New Compact SIMS at 61st AVS | Visit us on Booth 311 October 28th, 2014

Nanobiotechnology

Tiny carbon nanotube pores make big impact October 29th, 2014

Molecular beacons shine light on how cells 'crawl' October 27th, 2014

Breakthrough in molecular electronics paves the way for DNA-based computer circuits in the future: DNA-based programmable circuits could be more sophisticated, cheaper and simpler to make October 27th, 2014

NYU Researchers Break Nano Barrier to Engineer the First Protein Microfiber October 23rd, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE